Lenacapavir: An Overview’

  • Unique Paper ID: 158616
  • Volume: 9
  • Issue: 10
  • PageNo: 251-265
  • Abstract:
  • Lenacapavir was approved for medical use in European Union in August-2022, Lenacapavir is the first of a new class of drugs called "Capsid inhibitors to be FDA-approved for treating HIV/AIDS. Lenacapavir a new type of antiretroviral medication for adult patients living with Human Immunodeficiency Virus type-1(HIV-1), who’s HIV Infections cannot be successfully treated with other available treatments due to resistance, intolerance considerations. Lenacapavir works by blocking the HIV-1 virus' protein shell (the Capsid) .Lenacapvir, in combination with other antiretroviral(s), is indicated for the treatment of multidrug-resistant human immunodeficiency virus type-1 (HIV-1)-Infection. Lenacapvir first formulation Oral Tablets and Subcutaneous injection-form at trade Name-(Sunlenac), Lenacapavir -is achieved in HIV RNA suppression .Lenacapvir is a long- acting, potent inhibitor of the HIV Capsid protein. Lenacapavir binds directly to HIV-capsid in a pocket between capsid protein subunits in hexamers.Treatement of emergent resistance to lenacapvir has been reported in the phase 2/3 CAPELLA trail evaluating Lenacapvir for HIV treatment. Combination antiretroviral therapy-suppression HIV-1 replication and increase CD 4+ cell counts.

Cite This Article

  • ISSN: 2349-6002
  • Volume: 9
  • Issue: 10
  • PageNo: 251-265

Lenacapavir: An Overview’

Related Articles

Impact Factor
8.01 (Year 2024)

Join Our IPN

IJIRT Partner Network

Submit your research paper and those of your network (friends, colleagues, or peers) through your IPN account, and receive 800 INR for each paper that gets published.

Join Now

Recent Conferences

NCSEM 2024

National Conference on Sustainable Engineering and Management - 2024 Last Date: 15th March 2024

Submit inquiry